# PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer

Source: https://onco.cc/key-papers/paper-pharos-encorafenib-binimetinib-riely-jco-2023/  
OnCo record `paper-pharos-encorafenib-binimetinib-riely-jco-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A second BRAF and MEK inhibitor pair, encorafenib plus binimetinib, shrank tumours in three quarters of untreated and nearly half of previously treated patients with BRAF V600E lung cancer, giving a better-tolerated alternative to dabrafenib-trametinib.

## Summary

Phase 2 study of 98 patients with BRAF V600E-mutant metastatic non-small-cell lung cancer, 59 treatment-naive and 39 previously treated, given encorafenib plus binimetinib.

Objective response was 75 percent in treatment-naive and 46 percent in previously treated patients, with median duration of response not reached and 16.7 months respectively; pyrexia was less common than with dabrafenib-trametinib.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Journal of Clinical Oncology
- Year: 2023
- DOI: 10.1200/JCO.23.00774
- Authors: Riely GJ, Smit EF, Ahn MJ, et al.
- Findings: Objective response 75 percent (treatment-naive) and 46 percent (previously treated).; Median duration of response 16.7 months in previously treated patients.
- What it means: Encorafenib-binimetinib is approved for BRAF V600E lung cancer and offers a second targeted option, particularly for patients troubled by fever on dabrafenib-trametinib.
- Caveats: Single-arm; no head-to-head comparison with dabrafenib-trametinib.

## Sources

- J Clin Oncol 2023: https://doi.org/10.1200/JCO.23.00774
- PubMed: https://pubmed.ncbi.nlm.nih.gov/37270692/

## Connected records

- cancers: [BRAF V600E-mutant non-small-cell lung cancer](https://onco.cc/cancers/braf-v600e-nsclc/)
- drugs: [Binimetinib](https://onco.cc/drugs/binimetinib/), [Encorafenib](https://onco.cc/drugs/encorafenib/)
- trials: [PHAROS](https://onco.cc/trials/pharos/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-pharos-encorafenib-binimetinib-riely-jco-2023.json